IMAX Corporation — FY2023 Form 10-K
Business context and reporting period. Canadian-based IMAX operates a global premium cinema technology and content platform, earning revenue from film remastering and distribution, theater-system sales and leases, rentals, and maintenance. This annual report covers the year ended December 31, 2023; comparisons are primarily with FY2022. IMAX indirectly owned 71.55% of publicly traded IMAX China at year-end.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $374.8 million | $300.8 million |
| Gross margin | $214.3 million; 57% | $156.4 million; 52% |
| Operating income (loss) | $50.4 million | $(4.8) million |
| Net income (loss) attributable to common shareholders | $25.3 million; diluted EPS $0.46 | $(22.8) million; diluted EPS $(0.40) |
| Adjusted net income, non-GAAP | $52.1 million; diluted EPS $0.94 | $3.2 million; diluted EPS $0.06 |
| Net cash provided by operating activities | $58.6 million | $17.3 million |
Revenue rose 25%, and gross margin increased 37%. Content Solutions revenue grew 24% to $126.7 million, with segment gross margin of 58%; Technology Products and Services revenue grew 22% to $234.3 million, with segment gross margin of 55%. IMAX film global box office reached $1.1 billion, up 25%, including $180.4 million from Oppenheimer and more than $227 million from local-language films.
Cash and cash equivalents were $76.2 million at year-end, down from $97.4 million. Investing activities used $31.8 million and financing activities used $48.5 million. Gross debt was approximately $257.2 million, comprising $230 million of 0.500% convertible notes due April 2026 and $24 million drawn on the revolving facility, plus the Federal Economic Development Loan. Available borrowing capacity was $276.0 million under the Wells Fargo facility and a further $55.0 million under two China facilities. Total liabilities were $469.1 million. Management said it expects available cash and operating cash flows to fund anticipated needs and capital requirements over the following 12 months.
Material changes versus FY2022
- Net income attributable to common shareholders improved by $48.1 million, from a loss to a profit; operating results benefited from stronger box office, more system installations, and higher system signings.
- IMAX installed 128 systems versus 92 and signed 129 versus 47. Year-end network size increased to 1,772 systems from 1,716; backlog was 450 systems, flat year over year.
- Operating cash flow improved by $41.3 million. Cash nonetheless fell by $21.2 million, including share repurchases and investments.
- Credit-loss expense declined to $1.8 million from $8.5 million, when prior-year reserves included exposure related to Russia and the conflict with Ukraine.
- SG&A increased 5% to $144.4 million; R&D rose 91% to $10.1 million. FY2023 included $3.3 million of transaction costs related to the unsuccessful proposal to acquire IMAX China shares and $2.7 million of restructuring and executive transition costs.
Outlook, risks, contingencies, and unusual items
- No specific FY2024 revenue or earnings guidance is provided. Management expected further local-language films and exclusive events in 2024, and planned continued system expansion and technology investment. The announced film slate and release dates were subject to change.
- Greater China generated 25% of FY2023 revenue; 46% of system backlog, including upgrades, was in Greater China. Wanda represented 10% of revenue and was IMAX’s largest exhibitor customer. Box-office recovery, film availability, regulation, currency controls, and geopolitical tensions are material exposures.
- Backlog conversion depends on customer financing, theater construction, installation, and acceptance; management cautions that signed commitments may be delayed, modified, or not converted. Film performance, theatrical attendance, studio release schedules, exhibitor concentration, competition from streaming and other entertainment, and foreign-exchange movements also affect results.
- IMAX suspended operations in Russia and Belarus amid sanctions. Backlog included 14 Russian, one Ukrainian, and five Belarusian systems, with $22.9 million of fixed contracted value. Ukraine theaters resumed operations and related maintenance revenue and finance income were recognized in 2023.
- Convertible notes, revolving borrowings, debt covenants, variable-rate exposure, and long-term customer receivables create financing and collection risks. The company reported $64.3 million of variable-consideration receivables, whose ultimate collection depends partly on projected theater box office.
- An Indian arbitration award against E-City, including interest, was calculated by IMAX at $26.2 million as of year-end; enforcement remains pending, with no assurance of recovery. Management said other proceedings were not expected to materially affect financial position or future operating results.
- IMAX reported no cybersecurity incident that had materially affected its strategy, results, or financial condition. The auditor issued unqualified opinions on the financial statements and internal controls; the critical audit matter concerned system-sales revenue recognition and related estimates.
Most important facts for investors to verify
- Whether box-office growth, particularly in Greater China, continues and supports IMAX’s revenue-sharing income and premium ticket demand.
- Whether the 450-system backlog converts to installations, revenue, and cash; review customer delays, cancellations, and the concentration of backlog in China.
- Cash conversion and collection quality, including aging and allowances for accounts, financing, and variable-consideration receivables.
- Debt repayment and refinancing capacity ahead of the $230 million convertible-note maturity in 2026, covenant compliance, and the impact of share repurchases on liquidity.
- Progress and returns from streaming and consumer technology, including SSIMWAVE, and from ongoing R&D and joint-revenue-sharing system investments.
- Reconcile non-GAAP adjusted earnings with GAAP results and assess recurring versus unusual costs, tax effects, and the assumptions used to recognize system-sale revenue.